openPR Logo
Press release

Exclusive Pfizer Speaker Interview Released

12-12-2017 01:41 PM CET | Science & Education

Press release from: SMi Group

SMi are delighted to welcome Alison Betts, Associate Research Fellow, Pfizer, onto the speaker panel for day 1 at ADC 2018! www.adcsummit.com/opr

Alison is a member of the Translational Modeling & Simulation Group in the Biomedicines Design department at Pfizer, Cambridge MA, where she is modeling and simulation (M&S) lead supporting the Oncology Research Unit. In this role she leads a team responsible for using M&S strategies to answer mechanistic questions, validate targets, select optimal compounds, translate preclinical data to the clinic and predict efficacious dose/regimen.

SMi are excited to have interviewed Alison about her talk and career experience.

Below is a snapshot of her interview:

Q. How is your organisation involved in Antibodies and Antibody Drug Conjugates?

A. Pfizer has been heavily involved in the discovery and development of antibodies for many therapeutic indications and ADCs in oncology. For ADCs this has included design of novel linker payloads, design of ADCs to many novel targets and several clinical studies with ADCs. As noted above, recently 2 of Pfizer’s ADCs (Mylotarg and Besponza) were approved.

Q. What technology or platform updates have really caught your eye in the past couple of years?

A. I am interested in the masking technologies for design of ADCs against targets which may be present in normal tissues, but use of a specific mask enables targeting of the ADC to the tumour environment.

Q. What are the key areas for development in the field of ADCs?

A. Key areas for development in the field of ADCs are combination with immune-oncology check-point inhibitors and other cancer drugs for potentially curative therapies.

Q. What are the future challenges for the advancement of ADCs and what do you think are the biggest hindrances to achieving the utmost therapeutic potential of ADCs?

Check out the full interview, available in the download centre.

Hear more from Alison at the Antibodies & Antibody Drug Conjugates conference this April 2018, as she presents the Opening Address; 'Use of modelling and simulation to compare new generation HER-2 ADCs with Kadcyla™: a focus on PK and efficacy.'

- Day 1 | @09:10

Topics will explore:

- Kadcylaä is a HER-2 ADC approved in 2013 for patients with HER2+ metastatic breast cancer
- Kadcylaä is only efficacious in high HER2 tumors and patients are acquiring resistance
- New generation HER-2 ADCs are being designed to overcome these limitations
- PK/PD methodologies for efficacy and safety differentiation will be presented
- For PK predictions a mechanistic target mediated drug disposition model is proposed accounting for binding to shed HER-2 extracellular domain and variability across patients

More About Alison Betts:

Alison’s main area of work is on novel biotherapeutic modalities including bi-specific T-cell retargeting molecules, CAR-T cells, targeted nanoparticles and drug conjugates for treatment of cancer.

For those looking to attend there is currently a £400 early-bird saving, ending December 15th

Further information is available at: www.adcsummit.com/opr

SMi presents the 6th Annual Conference:

ADC Summit
Date: 9th – 10th April 2018
Location: Copthorne Tara Hotel, London UK
Website: www.adcsummit.com/opr

---end---

Contact Information:

For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Westminster Bridge Road
1

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Exclusive Pfizer Speaker Interview Released here

News-ID: 856860 • Views: 377

More Releases from SMi Group

Registration opens for SMi’s 4th Annual Ophthalmic Drugs Conference
SMi reports: Registration is now open for the 4th annual Ophthalmic Drugs Conference, taking place in London on the 23rd-24th November 2020. SMi presents the 4th Annual Ophthalmic Drugs Conference taking place on the 23rd-24th of November 2020, in London. The global ophthalmic drug market is forecast to surpass $60 billion USD by 2025 with increasing focus from the industry on alternative delivery approaches and improving the effectiveness of the current repertoire
US Air Force to Present Briefing on New PNT Constellation, NTS-3, at Military PN …
The US Space Force's new PNT constellation, Navigation Technology Satellite 3 (NTS-3), is designed to provide resilience to Global Navigation Satellite Systems by bringing online the M-Code, a long-delay signal that's more resilient to jamming. Not only is NTS-3 able to resist jamming, but its satellites can also be redeployed to provide coverage where it’s most needed. Currently being built by L3Harris under an $84 million contract, the constellation is expected
Fraunhofer Institute and German Aerospace Center To Brief on German SSA Perspect …
SMi Reports: The Fraunhofer Institute and German Aerospace Center (DLR) will be providing perspectives of German space situational awareness, including programme updates on TIRA and GESTRA The Fraunhofer Institute is currently operating the Tracking and Imaging Radar (TIRA) and developing the German Experimental Space Surveillance and Tracking Radar (GESTRA), both of which are essential parts of German military and civil SSA programmes. TIRA provides data about not only highly precise orbital
British Army to present on Maximising Tactical Awareness through Comprehensive A …
This year, it was announced that the British Army is facing a “modernisation challenge” as it looks to balance buying new equipment with upgrading its legacy fleet. A part of this is to continue with plans to update the capabilities of legacy vehicles Warrior and Challenger 2. The UK plans to upgrade 170 Challenger 2 MBTs with a life extension programme (LEP) to continue their utility through till 2035, and

All 5 Releases


More Releases for ADC

Application Delivery Controllers (ADC) Market Technology Advancement 2018 to 202 …
The application delivery controllers market is forecast to grow at a CAGR of over 6% during forecast period (2018 - 2023). The report elaborates the complete details covering product definition, product type, and application. The report covers useful details which are categorized based on Application Delivery Controllers (ADC) production region, major players, and product type which will provide a simplified view of the Application Delivery Controllers (ADC) industry. The Application Delivery
Global Application Delivery Controller (ADC) Market Analysis Research Report 201 …
MarketResearchReports.Biz has recently announced the Latest industry research report on: "Global Application Delivery Controller (ADC) Market Research Report 2018". This report studies the global Application Delivery Controller (ADC) market status and forecast, categorizes the global Application Delivery Controller (ADC) market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in United States, Europe, China, Japan, South Korea and Taiwan and other regions. An application
Application Delivery Controllers (ADC) Market, Global Analysis, Trends, Forecast …
An application delivery controller (ADC) is a computer networking device in a datacenter, usually a part of an application delivery network (ADN). It is generally deployed in data centers to optimize application performance, makes applications run faster, decreases the required bandwidth, ensures availability of applications, secure, and improves resource efficiency by offloading servers, providing deep payload inspection, and making efficient use of complex protocols. Earlier, ADC were deployed for externally-facing
Application Delivery Controllers (ADC) Market to 2025 – Analysis by QYResearch …
Qyresearchreports include new market research report “Global Application Delivery Controllers (ADC) Sales Market Report 2018” to its huge collection of research reports. The global Application Delivery Controllers (ADC) market is carefully examined in the report compiled with the use of latest research methodologies and up-to-date data. The researchers who have penned this report are experts in the subject and possess sound knowledge about the market. Moreover, they have immense experience in
SMi’s inaugural ADC Summit, 23rd & 24th May 2012, London
Antibody Drug Conjugates are used to fight cancerous cells and are made up of the antibody that will target a specific tumour0-associated antigen a drug often described as payload and the linker. This results in a drug being delivered selectively to the appropriate malignant cell due to the antibody targeting and specific antigen With less than a month away, join SMi at their inaugural ADC Summit conference that will provide a
ADC African Development Corporation GmbH & Co. KGaA: ADC exits shareholding in E …
ADC African Development Corporation (ADC), ISIN DE000A1E8NW9, a fast growing financial services group focusing on the frontier markets of sub-Saharan Africa, has successfully negotiated an exit for its 11.5% shareholding in Ecobank Zimbabwe for USD 5.2 million equaling approx. EUR 4.0 million. As of 30 September 2011, ADC had valued its shareholding in Ecobank Zimbabwe at EUR 1.25 million, so this transaction results in a realized profit of EUR 2.75